The scheduling review, prompted by Pres. Biden in October, could reshape the cannabis policy landscape in the U.S. Now, the DEA will decide.
The two-day FDLI conference focused on thorny questions in cannabis regulation, and included the FDA and other regulators.
On Thursday, the FDA pushed its desire to work with Congress on cannabinoid product rules, including delta-8 THC.
The FDA is seeking a “harm reduction framework” as it works with Congress on a path for CBD, according to the agency’s Cannabis Product Committee lead.
Amid Booming Cannabis Industry, State Insurance Regulators Call for “Safe Harbor” in New White Paper
A working group of the National Association of Insurance Commissioners plans to present the final paper at the Association’s Summer National Meeting in August.
Will the 2023 Farm Bill fix some of the confusion caused by the 2018 version that legalized hemp? State regulators and industry regulators hope Congress acts fast.
Norman Birenbaum spoke about the FDA’s cannabis-related efforts during a discussion on Thursday hosted by the Council for Federal Cannabis Regulation.
Norm Birenbaum, the FDA’s senior public health advisor on cannabis, spoke with Cannabis Wire about his new role and his priorities for 2023.
The cannabis industry has long-awaited rules from the FDA to guide the CBD industry. Now, it’s up to Congress.
The FDA’s long-awaited guidance for non-medical products containing CBD, which are already widely available despite being unregulated, is still in the works.
The group wants Congress to step in and pass legislation that could curb so-called “copycat” THC products, which are particularly appealing to kids.
During the SAMHSA Drug Testing Advisory Board meeting, officials discussed emerging trends with cannabis-derived isomers.
The FDA still has more questions than answers on CBD, but it is making strides on conducting the research and collecting the data needed to release product regulations.
The meeting, which will use cannabinoids as a “case study” in assessing the “safety” of certain foods and supplements, comes as the FDA wrestles with rulemaking for CBD products.
While cannabidiol products aren’t yet FDA approved for humans or animals, that hasn’t stopped plenty of sellers from marketing their products to treat, for example, animals’ anxiety.
A two-day event hosted by the Food and Drug Law Institute highlighted cannabis regulatory headaches, including delta-8 THC and a lack of uniformity in lab testing.